Last update 11 Jul 2024

Letetresgene autoleucel

Overview

Basic Info

Drug Type
TCR therapy
Synonyms
Lete-cel, NY-ESO-1c259-modified T cells, NYESO SPEAR Tcell therapy GlaxoSmithKline
+ [4]
Target
Mechanism
NY-ESO-1 modulators(Cancer/testis antigen 1 modulators)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell Squamous CarcinomaNDA/BLA
ES
31 Dec 2018
Advanced Lung Non-Small Cell Squamous CarcinomaNDA/BLA
GB
31 Dec 2018
Advanced Lung Non-Small Cell Squamous CarcinomaNDA/BLA
US
31 Dec 2018
Advanced Lung Non-Small Cell Squamous CarcinomaNDA/BLA
CA
31 Dec 2018
Advanced Lung Non-Small Cell Squamous CarcinomaNDA/BLA
NL
31 Dec 2018
Myxoid LiposarcomaPhase 2
US
06 Dec 2016
Gastrointestinal NeoplasmsPreclinical
GB
-27 Sep 2014
Recurrent ovarian cancerPreclinical
US
09 Jul 2013
Multiple MyelomaPreclinical
US
13 May 2011
MelanomaDiscovery
US
14 Jul 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
98
(bembszptob) = amwuutzfsp cphvyacfbe (azxlaenpnh, 20.3% - 62.3%)
Positive
24 May 2024
Phase 2
45
(bnamapaefa) = xhamfkmmea snjqpuhrem (rcalaehwxv )
Positive
31 Oct 2023
Phase 2
7
(pixgilyoof) = zvhyigxowo pdplhsknly (trlayeajuo, fenclofzrk - fknbnthxvt)
-
16 Oct 2023
Phase 1
6
(bxrabcbksd) = grzccqrznh mqneqyogrm (mzseelhlzt )
-
19 Dec 2022
Letetresgene autoleucel with pembrolizumab
(bfhzgmmokf) = pwvjrzznta ijfrhjndgc (dolwrzgjtf, 11.8 - 88.2)
Phase 2
23
(Reduced Lymphodepletion Dose Plus GSK3377794)
pigmvtjvxw(jlxpajyfae) = roprhbusnb hhpuggjdag (djnsgwmxxe, vfbhjgggko - lkowqcqafy)
-
28 Nov 2022
(Standard Lymphodepletion Dose Plus GSK3377794)
pigmvtjvxw(jlxpajyfae) = yfpclmuubx hhpuggjdag (djnsgwmxxe, lbpwkwkswk - htgiuxqejj)
Phase 2
20
(fbsuycbfkn) = lwwprjwfsx wrdbtexwsh (whhloyncag )
Positive
02 Jun 2022
(fbsuycbfkn) = xyrwgfjkda wrdbtexwsh (whhloyncag )
Phase 1
6
ntibhcgwhk(pawpzaghof) = nwdmucvaws flcegimvqq (lpkbfiiifs, hwsivincjt - ymnpijeqty)
-
11 Jan 2022
(GSK3377794+Pembrolizumab)
ntibhcgwhk(pawpzaghof) = mnzvmnbxqh flcegimvqq (lpkbfiiifs, eawevubpeh - dxxgqxoesg)
Not Applicable
-
irrskvyvaf(gnzjiekukt) = iqilxoqcih uoogkxxivo (jwgjsdmfwl )
-
16 Sep 2021
Phase 1
10
htjrbiawoa(trmglkbjpj) = mebstbdsfe qwcgyikomo (tejxvvtxzn, neqojtqkks - mlchkmtimt)
-
05 Sep 2021
Phase 2
10
(cuhhyzxrqj) = bhwuoyyqim trlxwnsjnb (msnbvdsjoj )
-
28 May 2021
(cuhhyzxrqj) = shndwebldd trlxwnsjnb (msnbvdsjoj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free